---
_id: '8245'
abstract:
- lang: eng
  text: "Background: Monoclonal antibodies (mAb), such as trastuzumab are a valuable
    addition to breast cancer therapy.\r\nData obtained from neoadjuvant settings
    revealed that antibody-dependent cell-mediated cytotoxicity (ADCC) is a\r\nmajor
    mechanism of action for the mAb trastuzumab. Conflicting results still call into
    question whether disease\r\nprogression, prolonged treatment or concomitant chemotherapy
    influences ADCC and related immunological\r\nphenomena.\r\nMethods: We analyzed
    the activity of ADCC and antibody-dependent cell-mediated phagocytosis (ADCP)
    of\r\nperipheral blood mononuclear cells (PBMCs) from human epidermal growth factor
    receptor 2 (HER2/neu) positive\r\nbreast cancer patients receiving trastuzumab
    therapy either in an adjuvant (n = 13) or metastatic (n = 15) setting as\r\nwell
    as from trastuzumab treatment-naive (t-naive) HER2/neu negative patients (n =
    15). PBMCs from healthy volunteers\r\n(n = 24) were used as controls. ADCC and
    ADCP activity was correlated with the expression of antibody binding\r\nFc-gamma
    receptor (FcγR)I (CD64), FcγRII (CD32) and FcγRIII (CD16) on CD14+ (monocytes)
    and CD56+ (NK) cells, as well as the expression of CD107a+ (LAMP-1) on CD56+ cells
    and the total amount of CD4+CD25+FOXP3+ (Treg) cells. In metastatic patients,
    markers were correlated with progression-free survival (PFS).\r\nResults: ADCC
    activity was significantly down regulated in metastatic, adjuvant and t-naive
    patient cohorts as compared to healthy controls. Reduced ADCC activity was inversely
    correlated with the expression of CD107a on CD56+\r\ncells in adjuvant patients.
    ADCC and ADCP activity of the patient cohorts were similar, regardless of treatment
    duration\r\nor additional chemotherapy. PFS in metastatic patients inversely correlated
    with the number of peripheral Treg cells.\r\nConclusion: The reduction of ADCC
    in patients as compared to healthy controls calls for adjuvant strategies, such
    as\r\nimmune-enhancing agents, to improve the activity of trastuzumab. However,
    efficacy of trastuzumab-specific ADCC\r\nand ADCP appears not to be affected by
    treatment duration, disease progression or concomitant chemotherapy. This\r\nfinding
    supports the application of trastuzumab at any stage of the disease."
article_number: '307'
article_processing_charge: No
author:
- first_name: Branka
  full_name: Petricevic, Branka
  last_name: Petricevic
- first_name: Johannes
  full_name: Laengle, Johannes
  last_name: Laengle
- first_name: Josef
  full_name: Singer, Josef
  last_name: Singer
- first_name: Monika
  full_name: Sachet, Monika
  last_name: Sachet
- first_name: Judit
  full_name: Fazekas, Judit
  id: 36432834-F248-11E8-B48F-1D18A9856A87
  last_name: Fazekas
  orcid: 0000-0002-8777-3502
- first_name: Guenther
  full_name: Steger, Guenther
  last_name: Steger
- first_name: Rupert
  full_name: Bartsch, Rupert
  last_name: Bartsch
- first_name: Erika
  full_name: Jensen-Jarolim, Erika
  last_name: Jensen-Jarolim
- first_name: Michael
  full_name: Bergmann, Michael
  last_name: Bergmann
citation:
  ama: Petricevic B, Laengle J, Singer J, et al. Trastuzumab mediates antibody-dependent
    cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant
    and metastatic HER2/neu breast cancer patients. <i>Journal of Translational Medicine</i>.
    2013;11. doi:<a href="https://doi.org/10.1186/1479-5876-11-307">10.1186/1479-5876-11-307</a>
  apa: Petricevic, B., Laengle, J., Singer, J., Sachet, M., Singer, J., Steger, G.,
    … Bergmann, M. (2013). Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity
    and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast
    cancer patients. <i>Journal of Translational Medicine</i>. Springer Nature. <a
    href="https://doi.org/10.1186/1479-5876-11-307">https://doi.org/10.1186/1479-5876-11-307</a>
  chicago: Petricevic, Branka, Johannes Laengle, Josef Singer, Monika Sachet, Judit
    Singer, Guenther Steger, Rupert Bartsch, Erika Jensen-Jarolim, and Michael Bergmann.
    “Trastuzumab Mediates Antibody-Dependent Cell-Mediated Cytotoxicity and Phagocytosis
    to the Same Extent in Both Adjuvant and Metastatic HER2/Neu Breast Cancer Patients.”
    <i>Journal of Translational Medicine</i>. Springer Nature, 2013. <a href="https://doi.org/10.1186/1479-5876-11-307">https://doi.org/10.1186/1479-5876-11-307</a>.
  ieee: B. Petricevic <i>et al.</i>, “Trastuzumab mediates antibody-dependent cell-mediated
    cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic
    HER2/neu breast cancer patients,” <i>Journal of Translational Medicine</i>, vol.
    11. Springer Nature, 2013.
  ista: Petricevic B, Laengle J, Singer J, Sachet M, Singer J, Steger G, Bartsch R,
    Jensen-Jarolim E, Bergmann M. 2013. Trastuzumab mediates antibody-dependent cell-mediated
    cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic
    HER2/neu breast cancer patients. Journal of Translational Medicine. 11, 307.
  mla: Petricevic, Branka, et al. “Trastuzumab Mediates Antibody-Dependent Cell-Mediated
    Cytotoxicity and Phagocytosis to the Same Extent in Both Adjuvant and Metastatic
    HER2/Neu Breast Cancer Patients.” <i>Journal of Translational Medicine</i>, vol.
    11, 307, Springer Nature, 2013, doi:<a href="https://doi.org/10.1186/1479-5876-11-307">10.1186/1479-5876-11-307</a>.
  short: B. Petricevic, J. Laengle, J. Singer, M. Sachet, J. Singer, G. Steger, R.
    Bartsch, E. Jensen-Jarolim, M. Bergmann, Journal of Translational Medicine 11
    (2013).
date_created: 2020-08-10T11:54:34Z
date_published: 2013-12-12T00:00:00Z
date_updated: 2022-08-25T14:52:39Z
day: '12'
ddc:
- '570'
doi: 10.1186/1479-5876-11-307
extern: '1'
external_id:
  pmid:
  - '24330813'
file:
- access_level: open_access
  content_type: application/pdf
  creator: dernst
  date_created: 2020-08-10T13:45:19Z
  date_updated: 2020-08-10T13:45:19Z
  file_id: '8247'
  file_name: 2013_JoTM_Petricevic.pdf
  file_size: 777311
  relation: main_file
  success: 1
file_date_updated: 2020-08-10T13:45:19Z
has_accepted_license: '1'
intvolume: '        11'
language:
- iso: eng
license: https://creativecommons.org/licenses/by/3.0/
month: '12'
oa: 1
oa_version: None
pmid: 1
publication: Journal of Translational Medicine
publication_identifier:
  issn:
  - 1479-5876
publication_status: published
publisher: Springer Nature
quality_controlled: '1'
status: public
title: Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis
  to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
tmp:
  image: /images/cc_by.png
  legal_code_url: https://creativecommons.org/licenses/by/3.0/legalcode
  name: Creative Commons Attribution 3.0 Unported (CC BY 3.0)
  short: CC BY (3.0)
type: journal_article
user_id: 3E5EF7F0-F248-11E8-B48F-1D18A9856A87
volume: 11
year: '2013'
...